Ab­b­Vie braces for 'greater ero­sion' of Hu­mi­ra fran­chise in sec­ond half of this year

Ab­b­Vie ex­ecs tout­ed a wave of Rin­voq pro­grams at Cowen’s an­nu­al con­fer­ence on health­care Tues­day as they brace for a tougher Hu­mi­ra bat­tle in the sec­ond half of this year.

Since its first ap­proval in rheuma­toid arthri­tis in 2002, Hu­mi­ra be­came one of in­dus­try’s top sell­ers ever, adding a wide list of in­di­ca­tions from ul­cer­a­tive col­i­tis to anky­los­ing spondyli­tis. The first biosim­i­lar to Hu­mi­ra, Am­gen’s Am­je­vi­ta, launched at the end of Jan­u­ary, and Ab­b­Vie ex­ecs an­nounced on the last quar­ter­ly call that they ex­pect a 37% drop in Hu­mi­ra sales this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER